Green approaches to the production of iopamidol

Iodinated contrast agents, such as iopamidol, are worldwide employed for performing a number of X-ray diagnostic procedures. Every year, thousands of tons of iodinated contrast agents are manufactured for the market with chemical processes that usually employ thionyl chloride. In this paper, we describe two new green approaches to iopamidol that avoid or reduce the use of this noxious reagent

A General MRI-CEST Ratiometric Approach for pH Imaging: Demonstration of in Vivo pH Mapping with Iobitridol

Chemical exchange saturation transfer (CEST) is a novel contrast mechanism for magnetic resonance imaging (MRI). CEST MRI selectively saturates exchangeable protons that are transferred to MRI-detectable bulk water signal. MRI-CEST (pH)-responsive agents are probes able to map pH in the microenvironment in which they distribute. To minimize the confounding effects of contrast agent concentration, researchers have developed ratiometric CEST imaging, which investigates contrast agents containing multiple magnetically non-equivalent proton groups, whose prototropic exchange have different pH responses. However, conventional ratiometric CEST MRI imposes stringent requirements on the selection of CEST contrasts agents. In this study, a novel ratiometric pH MRI method based on the analysis of CEST effects under different radio frequency irradiation power levels was developed. The proposed method has been demonstrated using iobitridol, an X-ray contrast agent analog of iopamidol but containing a single set of amide protons, both in vitro and in vivo

Cyclopentannulation of bicyclo[3.3.0]octane-3,7-dione. A more convenient synthesis of the [5]peristylane system

This article does not have an abstract

Understanding the structural specificity of Tn antigen for its receptor: An NMR solution study

The present work aims at understanding the structural basis of the biological recognition of Tn antigen (GalNAc-\u3b1-O-L-Ser), a specific epitope expressed by tumor cells, and the role of its amino acidic moiety in the interaction with its receptor (the isolectin B4 extracted from Vicia villosa). An NMR structural characterization of the \u3b1 and \u3b2 anomers, based on J couplings and molecular modeling revealed a structure in very good agreement with data reported in literature for variants of the same molecules. In order to demonstrate the involvement of the amino acid in the ligand\u2013receptor recognition, also GalNAc-\u3b1-O-D-Ser was studied; the change in the stereochemistry is in fact expected to impact on the interaction only in case the serine is part of the epitope. Relaxation properties in the presence of the receptor clearly indicated a selective recognition of the natural L form, probably due to the formation of a water-mediated hydrogen bond with Asn 129 of the protein

Arylsulfonamido compounds as metalloprotease inhibitors and their preparation, pharmaceutical compositions and use as diagnostic as well as radiotherapeutic agents

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R 1 , R 2 , R 3 , G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents

Diagnostic Agents Selective agains Metalloproteinases

The invention relates to aryl-sulfonamido compds. endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly labeled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their prepn., to pharmaceutical compns. comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents. The invention relates to arylsulfonamido compds. of formula I, which endowed with affinity against metalloproteases MMP and are useful as diagnostic imaging agents. The invention also refers to the process for their prepn., to pharmaceutical compns. comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents. Compds. of formula I wherein R is -Ar-X-Ar1; Ar is (un)substituted (hetero)arylene and (un)substituted (hetero)aryl; Ar1 is (un)substituted (hetero)aryl and H; X is a single bond, (un)branched C1-4 alkylene, O, S, SO2, CO, NH and derivs., NHCO and derivs., and CONH and derivs.; R1 is H, OH, Ra and ORa; Ra is (un)branched C1-4 alkyl, C2-4 alkenyl and - (CH2)0-4-Z-(CH2)0-4-W; Z is a single bond, O, NH and derivs., NHCO and derivs., and CONH and derivs.; W is (un)substituted Ph and (un)substituted 5- to 6-membered heterocycle; R2 and R3 are independently H, (un)substituted (un)branched C1-4 alkyl and a zinc binding group; G is (un)branched C1-6 alkyl, (hetero)aryl, arylalkyl and -(CH2)1-6- NH2 and derivs.; and their pharmaceutically acceptable salts thereof, are claimed. Example compd. II·2CF3COOH was prepd. via hydroxyamidation of the corresponding acid with O-(tert-butyldimethylsilyl)hydroxylamine. All the invention compds. were evaluated for their metalloprotease inhibitory activity. From the assay, it was detd. that II exhibited the IC50 value of 0.3 ± 0.03 nM and 0.2 ± 0.01 nM against MMP2 and MMP13, resp

Process for the iodination of phenolic derivates

The present invention relates to a process for the preparation of iodinated phenols; in particular; it relates to a process including the direct iodination, with suitably activated iodine, of 3,5-disubstituted phenol compounds to the corresponding 3,5-disubstituted-2,4,6-triiodophenols, which are useful intermediates for the synthesis of x-ray contrast media, and to the preparation of the contrast media themselves